In JoVE (1)

Other Publications (27)

Articles by Mark F Brady in JoVE

Other articles by Mark F Brady on PubMed

Pilot Evaluation of High-dose Carboplatin and Paclitaxel Followed by High-dose Melphalan Supported by Peripheral Blood Stem Cells in Previously Untreated Advanced Ovarian Cancer: a Gynecologic Oncology Group Study

Gynecologic Oncology. Jan, 2003  |  Pubmed ID: 12504619

To evaluate the efficacy and safety of multiple cycles of high-dose carboplatin and paclitaxel and one consolidation cycle of high-dose melphalan with all cycles supported by hematopoietic stem cells and cytokine, in previously untreated patients with optimally debulked stage III epithelial ovarian cancer.

Extraovarian Peritoneal Serous Papillary Carcinoma: a Phase II Trial of Cisplatin and Cyclophosphamide with Comparison to a Cohort with Papillary Serous Ovarian Carcinoma-a Gynecologic Oncology Group Study

Gynecologic Oncology. Apr, 2003  |  Pubmed ID: 12694669

The goals of this study were first, to assess the clinical effectiveness of cisplatin and cyclophosphamide in a phase II study involving a well-defined group of women with extraovarian peritoneal serous papillary carcinoma (EPSPC); and second, to compare these results with those of a group of patients with papillary serous ovarian carcinoma (PSOC) who received identical therapy.

Phase III Trial of Paclitaxel at Two Dose Levels, the Higher Dose Accompanied by Filgrastim at Two Dose Levels in Platinum-pretreated Epithelial Ovarian Cancer: an Intergroup Study

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Aug, 2003  |  Pubmed ID: 12807937

To determine if increasing the dose of paclitaxel increases the probability of clinical response, progression-free survival, or overall survival in women who have persistent or recurrent ovarian cancer, and whether doubling the dose of prophylactic filgrastim accompanying the higher paclitaxel dose decreases the frequency of neutropenic fever.

Adjuvant Treatment for Early Ovarian Cancer: a Randomized Phase III Trial of Intraperitoneal 32P or Intravenous Cyclophosphamide and Cisplatin--a Gynecologic Oncology Group Study

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Dec, 2003  |  Pubmed ID: 14645424

To conduct a prospective study of intraperitoneal radioactive chromic phosphate (32P) versus cyclophosphamide-cisplatin (CP) in women with early ovarian cancer at high risk for recurrence (International Federation of Gynecology and Obstetrics stage Ia or Ib grade 3 or Ic or stage II, no macroscopic residual disease) and to compare cumulative incidence of recurrence, overall survival, and relative toxicity. Materials and

Analysis of CHEK2 Gene for Ovarian Cancer Susceptibility

Gynecologic Oncology. Oct, 2004  |  Pubmed ID: 15385111

A deletion variant in the CHEK2 gene (del1100C) has been implicated as a low-penetrance risk factor for breast cancer. We sought to determine contribution of CHEK2 mutations to the etiology of ovarian cancer (OvCa).

Phase III Trial of Doxorubicin with or Without Cisplatin in Advanced Endometrial Carcinoma: a Gynecologic Oncology Group Study

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Oct, 2004  |  Pubmed ID: 15459211

Doxorubicin and cisplatin have activity in endometrial carcinoma and at initiation of this study ranked as the most active agents. This trial of stage III, IV, or recurrent disease evaluated whether combining these agents increases response rate (RR) and prolongs progression-free survival (PFS) and overall survival (OS) over doxorubicin alone.

Secondary Surgical Cytoreduction for Advanced Ovarian Carcinoma

The New England Journal of Medicine. Dec, 2004  |  Pubmed ID: 15590951

We evaluated the effect of adding secondary cytoreductive surgery to postoperative chemotherapy on progression-free survival and overall survival among patients who had advanced ovarian cancer and residual tumor exceeding 1 cm in diameter after primary surgery.

Randomized Phase III Trial of Three Versus Six Cycles of Adjuvant Carboplatin and Paclitaxel in Early Stage Epithelial Ovarian Carcinoma: a Gynecologic Oncology Group Study

Gynecologic Oncology. Sep, 2006  |  Pubmed ID: 16860852

Compared to 3 cycles, to determine if 6 cycles of adjuvant carboplatin (C) and paclitaxel (P) significantly lower the rate of recurrence in surgically staged patients with stage IA grade 3, IB grade 3, clear cell, IC, and completely resected stage II epithelial ovarian cancer (EOC); and to compare toxicities.

Intraperitoneal Therapy for Ovarian Cancer: a Treatment Ready for Prime Time

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Oct, 2006  |  Pubmed ID: 17008690

Effects of Initial Graft Tension on the Tibiofemoral Compressive Forces and Joint Position After Anterior Cruciate Ligament Reconstruction

The American Journal of Sports Medicine. Mar, 2007  |  Pubmed ID: 17218659

The initial tension applied to an anterior cruciate ligament graft at the time of fixation modulates knee motion and the tibiofemoral compressive loads.

Directly Observed Highly Active Antiretroviral Therapy for HIV-infected Children in Cambodia

American Journal of Public Health. Jun, 2007  |  Pubmed ID: 17463375

Antiretroviral medications are becoming available for HIV-infected children in resource-limited settings. Maryknoll, an international Catholic charity, provided directly observed antiretroviral therapy to HIV-infected children in Phnom Penh, Cambodia. Child care workers administered generic antiretroviral drugs twice daily to children, ensuring adherence. Treatment began with 117 late-stage HIV-infected children; 22 died of AIDS during the first 6 months. The rest were treated for at least 6 months and showed CD4 count increases comparable to those achieved in US and European children. Staffing cost for this program was approximately US $5 per child per month, or 15% more than the price of the medications. Drug toxicities were uncommon and easily managed. Directly observed antiretroviral therapy appears to be a promising, low-cost strategy for ensuring adherent treatment for HIV-infected children in a resource-limited setting.

A Gynecologic Oncology Group Randomized Phase III Trial of Whole Abdominal Irradiation (WAI) Vs. Cisplatin-ifosfamide and Mesna (CIM) As Post-surgical Therapy in Stage I-IV Carcinosarcoma (CS) of the Uterus

Gynecologic Oncology. Nov, 2007  |  Pubmed ID: 17822748

After initial surgery, there has been no established consensus regarding adjunctive therapy for patients with uterine carcinosarcoma (CS). This study was designed to compare patient outcome following treatment with adjuvant whole abdominal irradiation (WAI) versus (vs.) chemotherapy for patients with this rare group of female pelvic malignancies.

Phase III Randomized Trial of Intravenous Cisplatin Plus a 24- or 96-hour Infusion of Paclitaxel in Epithelial Ovarian Cancer: a Gynecologic Oncology Group Study

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Oct, 2007  |  Pubmed ID: 17906207

This study was undertaken to assess if prolonged paclitaxel administration in combination with cisplatin improves overall survival (OS) in epithelial ovarian cancer (EOC).

Corticosteroids Reduce Postoperative Morbidity After Third Molar Surgery: a Systematic Review and Meta-analysis

Journal of Oral and Maxillofacial Surgery : Official Journal of the American Association of Oral and Maxillofacial Surgeons. Sep, 2008  |  Pubmed ID: 18718396

The purpose of this study was to apply meta-analytical methods to measure the effect of corticosteroids (CS) on edema, trismus, and pain at early and late postoperative periods after third molar (M3) removal.

Tibiofemoral Compression Force Differences Using Laxity- and Force-based Initial Graft Tensioning Techniques in the Anterior Cruciate Ligament-reconstructed Cadaveric Knee

Arthroscopy : the Journal of Arthroscopic & Related Surgery : Official Publication of the Arthroscopy Association of North America and the International Arthroscopy Association. Sep, 2008  |  Pubmed ID: 18760214

Our purpose was to document the tibiofemoral (TF) compression forces produced during clinical initial graft tension protocols.

Evaluation of New Platinum-based Treatment Regimens in Advanced-stage Ovarian Cancer: a Phase III Trial of the Gynecologic Cancer Intergroup

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Mar, 2009  |  Pubmed ID: 19224846

To determine if incorporation of an additional cytotoxic agent improves overall survival (OS) and progression-free survival (PFS) for women with advanced-stage epithelial ovarian carcinoma (EOC) and primary peritoneal carcinoma who receive carboplatin and paclitaxel.

Congenital Trypanosoma Cruzi Transmission in Santa Cruz, Bolivia

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. Dec, 2009  |  Pubmed ID: 19877966

We conducted a study of congenital Trypanosoma cruzi infection in Santa Cruz, Bolivia. Our objective was to apply new tools to identify weak points in current screening algorithms, and find ways to improve them.

Microscopic Observation Drug Susceptibility Assay for Tuberculosis Screening Before Isoniazid Preventive Therapy in HIV-infected Persons

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. Apr, 2010  |  Pubmed ID: 20192727

Active tuberculosis (TB) must be excluded before initiating isoniazid preventive therapy (IPT) in persons infected with human immunodeficiency virus (HIV), but currently used screening strategies have poor sensitivity and specificity and high patient attrition rates. Liquid TB culture is now recommended for the detection of Mycobacterium tuberculosis in individuals suspected of having TB. This study compared the efficacy, effectiveness, and speed of the microscopic observation drug susceptibility (MODS) assay with currently used strategies for TB screening before IPT in HIV-infected persons.

Prognostic Relevance of Uncommon Ovarian Histology in Women with Stage III/IV Epithelial Ovarian Cancer

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. Aug, 2010  |  Pubmed ID: 20683400

The prognostic relevance of uncommon epithelial ovarian cancer (EOC) histological subtypes remains controversial. The Gynecologic Cancer InterGroup (GCIG) initiated this meta-analysis to assess the relative prognosis of women with a diagnosis of rare EOC histologies from completed, prospectively randomized studies performed by cooperative GCIG study groups.

Randomized Phase III Trial of Tamoxifen Versus Thalidomide in Women with Biochemical-recurrent-only Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma After a Complete Response to First-line Platinum/taxane Chemotherapy with an Evaluation of Serum Vascular Endothelial Growth Factor (VEGF): A Gynecologic Oncology Group Study

Gynecologic Oncology. Dec, 2010  |  Pubmed ID: 20846715

To compare progression-free survival (PFS), overall survival (OS) and toxicities of thalidomide versus tamoxifen and to evaluate serum vascular endothelial growth factor (VEGF) in biochemical-recurrent epithelial ovarian cancer, primary peritoneal cancer or fallopian tube carcinoma (EOC/PPC/FTC).

Advanced Stage Mucinous Adenocarcinoma of the Ovary is Both Rare and Highly Lethal: a Gynecologic Oncology Group Study

Cancer. Feb, 2011  |  Pubmed ID: 20862744

Primary mucinous adenocarcinomas of the ovary are uncommon, and their biological behavior is uncertain. Retrospective studies have suggested that many mucinous carcinomas initially diagnosed as primary to the ovary have in fact metastasized from another site. A prospective randomized trial provided an opportunity to estimate the frequency of mucinous tumors, diagnostic reproducibility, and clinical outcomes.

EORTC 55971: Does It Apply to All Patients with Advanced State Ovarian Cancer?

Gynecologic Oncology. Feb, 2011  |  Pubmed ID: 21093893

Improved Survival in Non-Ashkenazi Jewish Ovarian Cancer Patients with BRCA1 and BRCA2 Gene Mutations

Gynecologic Oncology. May, 2011  |  Pubmed ID: 21276604

Previous studies report a survival advantage in ovarian cancer patients with Ashkenazi Jewish (AJ) breast cancer gene (BRCA) founder mutations. The purpose of this study was to determine if this association exists in patients with non-Ashkenazi Jewish (non-AJ) BRCA mutations. We also sought to account for "survival bias" by minimizing lead time that may exist between diagnosis and genetic testing.

Nuclear P27 Expression in Benign, Borderline (LMP) and Invasive Tumors of the Ovary and Its Association with Prognosis: a Gynecologic Oncology Group Study

Gynecologic Oncology. May, 2011  |  Pubmed ID: 21310472

Nuclear p27 expression was examined in non-invasive and invasive ovarian tumors from a cross-sectional study, and clinical relevance of p27 was evaluated in the primary tumors from women participating in two randomized phase III treatment trials.

A Randomized Phase III Trial of IV Carboplatin and Paclitaxel × 3 Courses Followed by Observation Versus Weekly Maintenance Low-dose Paclitaxel in Patients with Early-stage Ovarian Carcinoma: a Gynecologic Oncology Group Study

Gynecologic Oncology. Jul, 2011  |  Pubmed ID: 21529904

To compare the recurrence-free interval (RFI) and safety profile in patients with completely resected high-risk early-stage ovarian cancer treated with intravenous (IV) carboplatin and paclitaxel with or without maintenance low-dose paclitaxel for 24 weeks.

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

The New England Journal of Medicine. Dec, 2011  |  Pubmed ID: 22204724

Vascular endothelial growth factor is a key promoter of angiogenesis and disease progression in epithelial ovarian cancer. Bevacizumab, a humanized anti-vascular endothelial growth factor monoclonal antibody, has shown single-agent activity in women with recurrent tumors. Thus, we aimed to evaluate the addition of bevacizumab to standard front-line therapy.

CA125 Regression in Ovarian Cancer Patients Treated with Intravenous Versus Intraperitoneal Platinum-based Chemotherapy: A Gynecologic Oncology Group Study

Gynecologic Oncology. Feb, 2012  |  Pubmed ID: 22033034

CA125 is a non-specific marker of peritoneal irritation which has the potential for false elevation during intraperitoneal treatment. The purpose of this study is to identify the rate of CA125 regression during intraperitoneal (IP) versus intravenous (IV) chemotherapy for ovarian cancer.

Waiting
simple hit counter